Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has issued an announcement.
Oxford Biomedica announced that its total issued share capital consists of 106,199,712 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to determine their interest in the company under the FCA’s rules, impacting how they manage their investments and disclosures.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s stock score is driven by strong earnings call insights and positive corporate events, indicating potential for future growth. However, financial performance remains a concern with high leverage and ongoing profitability challenges. Technical indicators suggest bullish momentum, but caution is advised due to potential overbought conditions.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in viral vector development and manufacturing. The company offers a range of unique technologies for viral vector manufacturing and operates facilities in the UK, France, and the US.
Average Trading Volume: 152,381
Technical Sentiment Signal: Buy
Current Market Cap: £467M
For detailed information about OXB stock, go to TipRanks’ Stock Analysis page.